GMP psilocybin

After a successful commercial production trial, life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) is set to begin commercial production of its clinical-grade psilocybin at a Good Manufacturing Practices (GMP) facility in January 2023. In addition to psilocybin, the company intends to...

With psilocybin among the favorites within psychedelics, Core One Labs Inc. (OTCQB: CLABF) is joining Optimi Health (OTC PINK: OPTHF) to formally begin sales for its own biosynthetic API psilocybin product. On August 26, the company began discussions with a development and...

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function, announced on Thursday its entry into an exclusive U.S. Distribution Agreement with California-based...